Why the study?
Does switching from phosphodiesterase type 5 inhibitors to riociguat improve outcomes in patients with PAH and CTEPH who cannot achieve treatment goals?
Does switching from phosphodiesterase type 5 inhibitors to riociguat improve outcomes in patients with PAH and CTEPH who cannot achieve treatment goals?
Answers are grounded in this paper and cite their sources.
This expert review outlines criteria for switching from phosphodiesterase type 5 inhibitors to riociguat in patients with PAH and CTEPH who fail to achieve treatment goals.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Lyapina et al. (2025) conducted a review in Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). Riociguat vs. Phosphodiesterase type 5 inhibitors was evaluated.
Synapse has enriched 10 related papers. Consider them for comparative context: